PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide.

お知らせ

News

06/13/2014
Patrick C Reid, Chief Scientific Officer at PeptiDream Inc (TSE 4587), Keynote Speaker Interview from 16th Annual TIDES Meeting.
04/14/2014
Patrick C Reid, Chief Scientific Officer at PeptiDream Inc (TSE 4587), will be a Keynote Speaker at the 16th Annual TIDES: Oligonucleotide and Peptide Therapeutics from Research through Commercialization Meeting – May 12-15, 2014 in Providence, Rhode Island, USA.
04/01/2014
Kevin Hudson, Associate Director of Oncology Bioscience at Astra Zeneca, Presented Findings on the PeptiDream Collaboration entitled “KRAS – A Test Case in Embracing New Drug Modalities” at Cambridge Cancer Science Symposium – March 25-26th, 2014.
03/18/2014
PeptiDream Inc. was named the 2014 Grand Prize winner at the Second Annual Japanese Business Model Society Meeting. The Japanese business model award is granted annually to the company that exhibits the most successful business model and is expected to achieve significant future growth.
02/07/2014
Non-consolidated Financial Results for the Six Months Ended December 31, 2013 [Japanese GAAP]
12/19/2013
PeptiDream and Lilly Announce Collaboration and License Agreement to Discover Macrocyclic Peptide Drug Candidates
11/28/2013
Patrick C Reid, Chief Scientific Officer at PeptiDream Inc (TSE 4587), will be an invited speaker at the Gordon Research Conference on Peptides, Chemistry & Biology of: Peptide Science in the Era of Synthetic Biology held in Ventura, California on February 23-28, 2014 and present on PeptiDream’s PDPS technology and macrocyclic peptide discovery efforts.
10/09/2013
PeptiDream and Doshisha University Report in the British Journal Nature Communications the Identification of C99-Binding Peptides that Selectively Inhibit the Production of Aβ in Vitro and In Vivo
10/07/2013
PeptiDream and Ipsen expand the scope of their collaboration for discovery of peptide drugs to treat serious endocrinologic disease
09/17/2013
PeptiDream Announces License of PeptiDream’s Peptide Discovery Platform System (PDPS) Technology to Bristol-Myers Squibb and Extension of the Macrocyclic Peptide Drug Discovery Alliance Between the Companies
08/19/2013
Patrick C Reid, Chief Scientific Officer at PeptiDream Inc (TSE 4587), will be an invited speaker at the 8th Annual Peptide Therapeutics Symposium at The Salk Institute in La Jolla, California October 24-25th, 2013 and present on PeptiDream’s PDPS technology and macrocyclic peptide discovery efforts.
08/13/2013
Non-consolidated Financial Results for the Fiscal Year Ended June 30, 2013 [Japanese GAAP]
06/11/2013
PeptiDream Inc shares start trading on the Tokyo Stock Exchange's Market of the High-growth and Emerging Stocks (Mothers: Ticker Code 4587). PeptiDream sold 2.7 million shares at Y2,500 per share in an initial public offering (IPO) and raised Y6.75billion (~$68 million).
05/08/2013
Announces approval for listing on the Tokyo Stock Exchange Mothers Market
04/10/2013
PeptiDream and Ipsen Enter into a Collaboration for Advancing Drug Discovery Efforts for Peptides to Treat Serious Disease
03/15/2013
PeptiDream Announces 2nd Milestone from Macrocylic Peptide Drug Discovery Alliance with Bristol-Myers Squibb
02/25/2013
PeptiDream Announces Expansion of Macrocylic Peptide Discovery Alliance with Amgen
02/15/2013
PeptiDream Announces Development Milestone from Macrocylic Peptide Drug Discovery Alliance with Bristol-Myers Squibb
02/15/2013
PeptiDream Announces Extension of Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb
01/15/2013
PeptiDream’s in vitro display technology “PD Display” patent granted in Japan
01/09/2013
PeptiDream wins Grand Prize Award as top “Japan Bioventure”.
12/01/2012
PeptiDream Announces Extension of Macrocylic Peptide Drug Discovery Alliance with Novartis, and that Novartis has taken an Equity Stake in PeptiDream.

IRニュース

IR News

PeptiDream Inc. is a publically-listed (“PeptiDream”)(Tokyo:4587) Tokyo-based biopharmaceutical company employing our proprietary PDPS (Peptide Discovery Platform System) , a state-of-the-art highly versatile peptide generation and selection platform which enables the production of highly diverse non-standard peptide libraries with high efficiency, for the discovery and development of best-in-class and first-in-class peptide-based therapeutics. PeptiDream aspires to be a world leader in the discovery and development of novel highly functional peptide therapeutics to address unmet medical needs and improve the quality of life of patients worldwide..